Doxorubicin hydrochloride-carrying natural polymer-poly(3-benzene acid acrylamide) composite nanospheres, manufacturing method and application thereof

A technology of acrylamidophenylboronic acid and natural polymers, which is applied in the direction of non-active ingredients of polymer compounds, preparation of microspheres, medical preparations of non-active ingredients, etc., to achieve good biocompatibility, strong drug sustained release function, The effect of chemical stability

Active Publication Date: 2010-11-10
NANJING UNIV
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, natural polymer-poly(3-acrylamidophenylbo...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Doxorubicin hydrochloride-carrying natural polymer-poly(3-benzene acid acrylamide) composite nanospheres, manufacturing method and application thereof
  • Doxorubicin hydrochloride-carrying natural polymer-poly(3-benzene acid acrylamide) composite nanospheres, manufacturing method and application thereof
  • Doxorubicin hydrochloride-carrying natural polymer-poly(3-benzene acid acrylamide) composite nanospheres, manufacturing method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1: Preparation of dextran-poly(3-acrylamidophenylboronic acid) composite nanospheres

[0030] In a 25 ml stirred reactor, 90 mg of 3-acrylamidophenylboronic acid and 152 mg of dextran with a number average molecular weight of 3000 were dissolved in 12 ml of distilled water. After cooling to room temperature, 9.4 mg of 4,4'-azo(4-cyanovaleric acid) initiator was added. The temperature was raised to 80° C., and the polymerization reaction was initiated for 2 hours to obtain an aqueous solution of dextran-poly(3-acrylamidophenylboronic acid) composite nanospheres. Stop the reaction, lower the system temperature to room temperature, put the aqueous dispersion into a dialysis bag (Cut-off molecular weight: 12000) and dialyze for 24 hours to remove unreacted monomers in the system. The average particle size of the nanospheres measured by dynamic light scattering is 72.5±2.0 nm. Among them, natural polymer accounts for 9.1%, and poly(3-acrylamidophenylboronic acid...

Embodiment 2

[0031] Embodiment 2: Preparation of dextran-poly(3-acrylamidophenylboronic acid) composite nanospheres

[0032]In a 25 ml stirred reactor, 90 mg of 3-acrylamidophenylboronic acid and 76 mg of dextran with a number average molecular weight of 3000 were dissolved in 12 ml of distilled water. After cooling to room temperature, 9.4 mg of 4,4'-azo(4-cyanovaleric acid) initiator was added. The temperature was raised to 80° C., and the polymerization reaction was initiated for 2 hours to obtain an aqueous solution of dextran-poly(3-acrylamidophenylboronic acid) composite nanospheres. Stop the reaction, lower the temperature of the system to room temperature and filter. After filtration, put the aqueous dispersion into a dialysis bag (cut-off molecular weight: 12000) and dialyze for 24 hours to remove unreacted monomers in the system. The average particle size of the nano-microspheres measured by dynamic light scattering is 77.4±2.1 nm, wherein natural polymer accounts for 4.2%, and ...

Embodiment 3

[0033] Embodiment 3: Preparation of dextran-poly(3-acrylamidophenylboronic acid) composite nanospheres

[0034] In a 25 ml stirred reactor, 90 mg of 3-acrylamidophenylboronic acid and 38 mg of dextran with a number average molecular weight of 3000 were dissolved in 12 ml of distilled water. After cooling to room temperature, 9.4 mg of 4,4'-azo(4-cyanovaleric acid) initiator was added. The temperature was raised to 80° C., and the polymerization reaction was initiated for 2 hours to obtain an aqueous solution of dextran-poly(3-acrylamidophenylboronic acid) composite nanospheres. Stop the reaction, lower the temperature of the system to room temperature and filter. After filtration, put the aqueous dispersion into a dialysis bag (cut-off molecular weight: 12000) and dialyze for 24 hours to remove unreacted monomers in the system. The average particle size of the nano-microspheres measured by dynamic light scattering is 65.1±0.1 nm, wherein natural polymer accounts for 2.5%, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses natural polymer-poly(3-benzene acid acrylamide) composite nanospheres. The surfaces of the natural polymer-poly(3-benzene acid acrylamide) composite nanospheres are hydrophilic natural polymers; the interiors are hydrophobic poly(3-benzene acid acrylamide); the number average molecular weight of the natural polymer is in a range of between 2,000 and 100,000; the content ofthe natural polymer is 5 to 70 percent of the mass of the composite nanospheres; the number average molecular weight of the poly(3-benzene acid acrylamide) is in a range of between 1,000 and 10,000; the content of the poly(3-benzene acid acrylamide) is 30 to 95 percent of the mass of the composite nanospheres; and the average grain diameter of the composite nanospheres is of between 40 and 100 nanometers. The composite nanospheres of the invention have the characteristics of high biocompatibility and stable chemical properties. The composite nanospheres of the invention can be used as a medicament carrier, has a sustained-release effect, and can be used as a carrying agent in a boron neutron capture therapy. The invention also discloses a manufacturing method for the composite nanospheres.

Description

technical field [0001] The invention relates to a biodegradable natural polymer-poly(3-acrylamide phenylboronic acid) composite nano microsphere, which can be used as boron neutron capture therapy and also as a drug carrier. Background technique [0002] Boron neutron capture therapy (BNCT) is a treatment that destroys cancer cells through nuclear reactions within tumor cells. Its treatment principle is to inject isotopes into tumor patients first. 10 Boron, after boron enters the body, accumulates in tumor cells, while other tissues are rarely distributed. This boron-containing compound is non-toxic to humans and has no therapeutic effect on cancer. Irradiate the tumor site with a thermal neutron ray, 1 neutron radiation 10 Boron atom absorbs 1 neutron to become 11 Boron atom undergoes nuclear fission, and the fission releases alpha particles ( 4 He) and lithium atoms ( 7 Li). Alpha particles are extremely lethal rays, which can effectively kill tumor cells, and are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): B01J13/02A61K41/00A61K47/32A61K47/36A61K47/38A61K47/42A61K31/704A61P35/00
Inventor 蒋锡群张鲁中武伟王晶
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap